Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
The FDA approval of esketamine nasal spray (Spravato) in 2019 for treatment-resistant depression brought significant attention to ketamine-based treatments. But many patients and even some clinicians are unclear about the relationship between esketamine and the racemic ketamine that has been used off-label for years. Are they the same drug? Does one work better? The answer involves some important chemistry and a growing body of comparative evidence.
Ketamine is a chiral molecule, meaning it exists in two mirror-image forms: S-ketamine (esketamine) and R-ketamine (arketamine). Standard pharmaceutical ketamine is "racemic" — it contains a 50/50 mixture of both forms. Esketamine, the S-enantiomer, has approximately four times greater binding affinity for the NMDA receptor compared to arketamine, which is why it was initially assumed to be the more potent antidepressant.
Esketamine nasal spray was approved by the FDA based on a series of Phase 3 clinical trials led by Janssen Pharmaceuticals. The pivotal trial by Popova et al. (2019), published in the American Journal of Psychiatry, demonstrated that esketamine nasal spray plus a newly initiated oral antidepressant was superior to placebo nasal spray plus a newly initiated oral antidepressant in adults with treatment-resistant depression. This led to FDA approval under the brand name Spravato, which must be administered in a certified healthcare setting under observation.
Comparative studies between esketamine and racemic ketamine remain limited, but the available evidence is informative. Correia-Melo and colleagues published a non-inferiority trial in Medicine in 2020 comparing IV esketamine to IV racemic ketamine in patients with treatment-resistant depression. The study found that racemic ketamine was non-inferior to esketamine, and in some secondary measures, racemic ketamine showed numerically greater improvement. Both treatments were well tolerated, though side effect profiles differed modestly — esketamine tended to produce more dissociation at equivalent antidepressant doses.
Interestingly, preclinical research suggests that arketamine (the R-enantiomer, present in racemic ketamine but absent from esketamine) may have antidepressant properties of its own, potentially through different downstream signaling pathways including AMPA receptor activation and BDNF release. This raises the possibility that racemic ketamine's inclusion of both enantiomers may offer a broader pharmacological profile.
The clinical distinction between esketamine and racemic ketamine has practical implications for patients. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and for depressive symptoms with acute suicidal ideation or behavior, but it must be administered in a REMS-certified healthcare facility with a two-hour post-dose observation period. It is typically covered by insurance, though prior authorization requirements are common.
Racemic ketamine, by contrast, is prescribed off-label. It is available in multiple formulations — intravenous, sublingual, and intranasal — and can be prescribed by physicians for at-home use in sublingual form. It is generally less expensive per dose than Spravato, though it is not typically covered by insurance for mental health indications.
From an efficacy standpoint, the available evidence does not clearly establish one as superior to the other. The Correia-Melo non-inferiority trial suggests comparable antidepressant effects, and some clinicians observe that racemic ketamine may provide a broader therapeutic profile due to the inclusion of the R-enantiomer. However, head-to-head randomized controlled trials with adequate sample sizes are still needed.
If you're deciding between esketamine and racemic ketamine, the choice may come down to access, cost, and clinical context. Esketamine has the advantage of FDA approval and potential insurance coverage, but requires in-office administration. Racemic ketamine, particularly in sublingual form, can be taken at home under physician supervision and is often more affordable out of pocket.
Neither option is inherently "better." Both act on the NMDA receptor system, both have demonstrated antidepressant effects in clinical studies, and both carry similar side effect profiles. Your physician can help you weigh the trade-offs based on your specific situation, insurance coverage, and treatment preferences.
Esketamine and racemic ketamine are related but pharmacologically distinct. Current evidence suggests comparable antidepressant efficacy, though they differ in FDA approval status, administration requirements, and cost. The choice between them often depends on practical factors including access, insurance coverage, and whether at-home treatment is preferred.
References: Correia-Melo FS, Leal GC, Vieira F, et al. "Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial." Medicine. 2020;99(38):e22028.
Popova V, Daly EJ, Trivedi M, et al. "Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression." American Journal of Psychiatry. 2019;176(6):428-438.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
